Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
AGEN 
Agenus Inc (AGEN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: AGEN (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
5 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $12.33
1 Year Target Price $12.33
| 1 | Strong Buy |
| 1 | Buy |
| 3 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -62.3% | Avg. Invested days 31 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 129.05M USD | Price to earnings Ratio - | 1Y Target Price 12.33 |
Price to earnings Ratio - | 1Y Target Price 12.33 | ||
Volume (30-day avg) 5 | Beta 1.43 | 52 Weeks Range 1.38 - 7.34 | Updated Date 10/14/2025 |
52 Weeks Range 1.38 - 7.34 | Updated Date 10/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -7.06 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -162.69% | Operating Margin (TTM) -65.32% |
Management Effectiveness
Return on Assets (TTM) -23.93% | Return on Equity (TTM) -1278.83% |
Valuation
Trailing PE - | Forward PE 3.52 | Enterprise Value 206538585 | Price to Sales(TTM) 1.27 |
Enterprise Value 206538585 | Price to Sales(TTM) 1.27 | ||
Enterprise Value to Revenue 2.03 | Enterprise Value to EBITDA -2.42 | Shares Outstanding 31864108 | Shares Floating 31305849 |
Shares Outstanding 31864108 | Shares Floating 31305849 | ||
Percent Insiders 1.75 | Percent Institutions 30.18 |
Upturn AI SWOT
Agenus Inc
Company Overview
History and Background
Agenus Inc., founded in 1994, is an immuno-oncology company focused on developing and commercializing therapies to activate the immune system against cancer. It evolved from Lexington BioScience, focusing initially on vaccine adjuvants and expanding into checkpoint antibodies and cell therapies.
Core Business Areas
- Checkpoint Antibodies: Development of novel checkpoint antibodies, including botensilimab, to enhance anti-tumor immunity.
- Cell Therapies: Development of adoptive cell therapies, including next-generation T-cell therapies, to target and destroy cancer cells.
- Vaccine Adjuvants: Discovery and development of vaccine adjuvants to enhance the immune response to vaccines, licensed to pharmaceutical partners.
Leadership and Structure
Dr. Garo Armen is the Chairman and CEO. The company has a management team overseeing research and development, clinical development, and commercial operations. Agenus operates with a typical biotech structure.
Top Products and Market Share
Key Offerings
- Botensilimab: A next-generation CTLA-4 antibody designed to enhance anti-tumor activity. Currently in clinical trials for various solid tumors. Market share is nascent, awaiting FDA approval. Competitors include Bristol Myers Squibb (Yervoy), Merck (Keytruda) when used in combination, and other companies with CTLA-4 inhibitors.
- AGEN1181 (Balstilimab): An anti-PD-1 antibody approved for cervical cancer but licensed to another party. Agenus receives royalties. Market share info for balstilimab after licensing is tracked by the license holder and isn't publicly available. Key competitors include Merck (Keytruda) and Regeneron (Libtayo) .
- QS-21 Stimulon Adjuvant: A vaccine adjuvant used in GSK's Shingrix shingles vaccine. Agenus receives royalties. Shingrix has a significant market share in the shingles vaccine market. Competitors are primarily Merck's Zostavax (now discontinued).
Market Dynamics
Industry Overview
The immuno-oncology industry is experiencing rapid growth, driven by advances in understanding the immune system's role in cancer and the development of novel immunotherapies. Key trends include combination therapies, personalized medicine, and CAR-T cell therapies.
Positioning
Agenus is positioned as an innovative immuno-oncology company focused on developing next-generation checkpoint antibodies and cell therapies. Its competitive advantage lies in its differentiated antibody designs and adjuvant platform.
Total Addressable Market (TAM)
The TAM for immuno-oncology is estimated to be in the tens of billions of dollars annually and growing. Agenus is targeting specific segments of this market, particularly solid tumors, with its botensilimab program.
Upturn SWOT Analysis
Strengths
- Novel checkpoint antibody design (botensilimab)
- Strong vaccine adjuvant platform (QS-21 Stimulon)
- Experienced management team
- Strategic partnerships with major pharmaceutical companies
Weaknesses
- Reliance on clinical trial success
- Significant cash burn
- Competition from established players
- Regulatory hurdles for new therapies
Opportunities
- FDA approval of botensilimab
- Expansion of cell therapy pipeline
- Further partnerships and licensing deals
- Application of adjuvants in new vaccine development
Threats
- Clinical trial failures
- Regulatory setbacks
- Competition from new immunotherapies
- Economic downturn impacting healthcare spending
Competitors and Market Share
Key Competitors
- BMY
- MRK
- PFE
- GSK
Competitive Landscape
Agenus faces intense competition from established pharmaceutical companies with greater resources and broader product portfolios. Its advantages lie in its innovative technologies and strategic partnerships.
Major Acquisitions
Profectus BioSciences
- Year: 2018
- Acquisition Price (USD millions): 53
- Strategic Rationale: Expanded Agenus's pipeline with novel cancer vaccine and oncolytic virus programs.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been characterized by periods of rapid advancement of drug candidates in clinical trials, followed by revenue recognition from licensing deals, resulting in high volatility.
Future Projections: Future growth is dependent on the success of botensilimab and other pipeline programs. Analyst estimates vary widely based on the perceived probability of clinical trial success and regulatory approval. Revenue is forecast to increase significantly after potential commercialization.
Recent Initiatives: Recent initiatives include advancing botensilimab in multiple clinical trials, expanding the cell therapy platform, and seeking new partnerships.
Summary
Agenus is a biotech company with innovative immunotherapy technologies. Its success hinges on the positive clinical trial results of its lead candidate, botensilimab. Agenus should look out for clinical trial failures and competition from established players. Partnerships are key to its financial stability.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Agenus Inc. SEC Filings
- Industry Reports
- Analyst Reports
- Company Website
Disclaimers:
This analysis is for informational purposes only and does not constitute investment advice. Market share data is estimated and subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Agenus Inc
Exchange NASDAQ | Headquaters Lexington, MA, United States | ||
IPO Launch date 2000-02-04 | Founder, Executive Chairman & CEO Dr. Garo H. Armen Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 316 | Website https://www.agenusbio.com |
Full time employees 316 | Website https://www.agenusbio.com | ||
Agenus Inc., a clinical-stage biotechnology company, discovers and develops therapies to activate the body's immune system against cancer and infections in the United States and internationally. It offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, a programmed death receptor-1 (PD-1) blocking antibody; AGEN1181, a human Fc-enhanced cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody that is in Phase 2 trials in metastatic colorectal cancer (mCRC), pancreatic cancer, and melanoma; AGEN2373, a CD137 monospecific antibody that is in Phase 1b clinical trial; AGEN1423, a CD73/TGFß TRAP antibody; AGEN1571, an ILT2 monospecific antibody that is in clinical development; and BMS-986442, a TIGIT bispecific antibodies. In addition, it develops INCAGN1876, a GITR agonist; INCAGN2390, a TIM-3 monoclonal antibodies; INCAGN2385, a LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4 that is in Phase 2 clinical trial; UGN-301, a zalifrelimab intravesical solution for the treatment of cancers of the urinary tract t; and AGEN1884. The company operates under the Agenus, MiNK, Prophage, Retrocyte Display, and STIMULON trademarks. It has collaborations with Bristol-Myers Squibb Company, Betta Pharmaceuticals Co., Ltd., UroGen Pharma Ltd., Gilead Sciences, Inc., Incyte Corporation, and Merck Sharp & Dohme. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.